Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) Stock Short Interest Report for October

Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) was the target of a large increase in short interest in October. As of October 15th, there was short interest totaling 229,146 shares, an increase of 1,343.5% from the September 30th total of 15,874 shares. Currently, 0.1% of the company’s stock are sold short. Based on an average daily volume of 954,798 shares, the days-to-cover ratio is currently 0.2 days.

Oncotelic Therapeutics Stock Down 3.6%

Shares of OTLC stock traded down $0.00 during trading hours on Monday, hitting $0.02. 342,035 shares of the company were exchanged, compared to its average volume of 407,391. The company has a debt-to-equity ratio of 0.01, a quick ratio of 0.08 and a current ratio of 0.08. Oncotelic Therapeutics has a one year low of $0.01 and a one year high of $0.11. The business’s 50-day simple moving average is $0.03 and its two-hundred day simple moving average is $0.04. The stock has a market capitalization of $7.44 million, a price-to-earnings ratio of 0.03 and a beta of -0.18.

About Oncotelic Therapeutics

Oncotelic Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics for cancer and other serious diseases. The company’s research has centered on RNA-based medicines and treatments designed to target biological pathways involved in tumor growth, immune regulation and disease progression.

Its lead product candidate, OT-101, is an antisense oligonucleotide designed to inhibit transforming growth factor beta 2 (TGF-β2), a signaling protein associated with tumor development and immune suppression.